Overview

  • Product nameAnti-KCNC3 antibody
    See all KCNC3 primary antibodies
  • Description
    Mouse monoclonal to KCNC3
  • Tested applicationsSuitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Recombinant fragment: ALAHEDCPAI DQPAMSPEDK SPITPGSRGR YSRDRACFLL TDYAPSPDGS IRKATGAPPL PPQDWRKPGP PSFLPDLNAN AAAWISP, corresponding to amino acids 671-758 of Human KCNC3

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    PBS, pH 7.2
  • Concentration information loading...
  • PurityProtein G purified
  • ClonalityMonoclonal
  • IsotypeIgG1
  • Light chain typekappa
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab55272 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 5 µg/ml. Predicted molecular weight: 81 kDa.
ICC/IF Use a concentration of 10 µg/ml.

Target

  • FunctionThis protein mediates the voltage-dependent potassium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a potassium-selective channel through which potassium ions may pass in accordance with their electrochemical gradient.
  • Involvement in diseaseDefects in KCNC3 are the cause of spinocerebellar ataxia type 13 (SCA13) [MIM:605259]. Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA13 is an autosomal dominant cerebellar ataxia (ADCA) characterized by slow progression and variable age at onset, ranging from childhood to late adulthood. Mental retardation can be present in some patients.
  • Sequence similaritiesBelongs to the potassium channel family. C (Shaw) (TC 1.A.1.2) subfamily. Kv3.3/KCNC3 sub-subfamily.
  • DomainThe segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.
    The tail may be important in modulation of channel activity and/or targeting of the channel to specific subcellular compartments.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Kcnc3 antibody
    • KCNC3_HUMAN antibody
    • KSHIIID antibody
    • KV3.3 antibody
    • Potassium voltage gated channel Shaw related subfamily member 3 antibody
    • Potassium voltage gated channel subfamily C member 3 antibody
    • Potassium voltage-gated channel subfamily C member 3 antibody
    • SCA13 antibody
    • Shaw related subfamily, member 3 antibody
    • Shaw related voltage gated potassium channel protein 3 antibody
    • Spinocerebellar ataxia 13 antibody
    • Voltage gated potassium channel protein KV3.3 antibody
    • Voltage gated potassium channel subunit Kv3.3 antibody
    • Voltage-gated potassium channel subunit Kv3.3 antibody
    see all

Anti-KCNC3 antibody images



  • Predicted band size : 81 kDa
    KCNC3 antibody (ab55272) at 1ug/lane + NIH/3T3 cell lysate at 25ug/lane.
  • ab55272 at 10 ug/ml staining KCNC3 in human Hella cells by Immunocytochemistry/ Immunofluorescence.

References for Anti-KCNC3 antibody (ab55272)

ab55272 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab55272.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"